Target intelligence / Profile preview

Class E basic helix-loop-helix protein 41 (BHLHE41)

Target
BHLHE41
Molecular classification
Transcription factor, Basic helix-loop-helix (bHLH) protein superfamily
01

Overview

Class E basic helix-loop-helix protein 41 (BHLHE41) is a nuclear transcriptional repressor and member of the bHLH protein superfamily, functioning predominantly through dimerization and binding E-box elements in DNA to regulate gene expression. It modulates differentiation, circadian rhythms, DNA repair, cell cycle, apoptosis, and immune responses. BHLHE41 acts as either a tumor suppressor or oncogene depending on tissue context and is implicated in the biology of several cancers and hematological malignancies, as well as rare familial sleep phenotypes. Owing to its central regulatory role, dysregulation of BHLHE41 can contribute to oncogenesis and is under investigation as both a potential biomarker and therapeutic target. No approved drugs directly target BHLHE41, and its complex, sometimes opposing, functions in physiology and disease represent ongoing challenges for therapeutic exploitation[1][2][4].

Other names
Class E basic helix-loop-helix protein 41BHLHB3DEC2SHARP1bHLHe41bHLHb3hDEC2SHARP-1Differentially expressed in chondrocytes protein 2FNSS1enhancer-of-split and hairy-related protein 1
02

Biological functions

Transcriptional repressionRegulation of circadian rhythmControl of cell differentiationDNA repairRegulation of myogenesis (muscle development)Regulation of mesenchymal stem cell fateRegulation of immune cell differentiation (Th2 cells, B cells)Regulation of cell cycle and apoptosis
03

Disease associations

CancerHematological malignancies (e.g., multiple myeloma, acute myeloid leukemia)Short sleep phenotype/Familial natural short sleepPotential biomarker in cancersImplicated in pathogenesis of non-Hodgkin lymphoma, myeloma, and inflammatory conditions
04

Safety considerations

Potential tumor suppressor or oncogenic function is context-dependent, representing a therapeutic challenge[1]Complex regulation and diverse biological roles complicate targeting[1]
05

Biomarkers

Expression levels in multiple myeloma and acute myeloid leukemia may predict poor prognosis[1]Overexpression observed in ovarian, stomach, and thyroid cancers[1]

Beyond the preview

Go deeper on Class E basic helix-loop-helix protein 41 (BHLHE41).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Class E basic helix-loop-helix protein 41 (BHLHE41).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call